Zynex Inc. (ZYXI): Price and Financial Metrics

Zynex Inc. (ZYXI): $13.51

-0.02 (-0.15%)

POWR Rating

Component Grades














  • Quality is the dimension where ZYXI ranks best; there it ranks ahead of 98.67% of US stocks.
  • ZYXI's strongest trending metric is Stability; it's been moving up over the last 178 days.
  • ZYXI's current lowest rank is in the Growth metric (where it is better than 22.81% of US stocks).

ZYXI Stock Summary

  • The price/operating cash flow metric for ZYNEX INC is higher than 84.09% of stocks in our set with a positive cash flow.
  • Of note is the ratio of ZYNEX INC's sales and general administrative expense to its total operating expenses; 86.8% of US stocks have a lower such ratio.
  • Over the past twelve months, ZYXI has reported earnings growth of 87.8%, putting it ahead of 83.38% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ZYNEX INC, a group of peers worth examining would be SAFT, AVD, VPG, HGBL, and STRT.
  • ZYXI's SEC filings can be seen here. And to visit ZYNEX INC's official web site, go to www.zynex.com.

ZYXI Valuation Summary

  • ZYXI's price/earnings ratio is 27.4; this is 18.1% higher than that of the median Healthcare stock.
  • Over the past 193 months, ZYXI's EV/EBIT ratio has gone up 23.9.

Below are key valuation metrics over time for ZYXI.

Stock Date P/S P/B P/E EV/EBIT
ZYXI 2022-11-25 3.4 7.8 27.4 21.0
ZYXI 2022-11-23 3.5 8.0 28.0 21.4
ZYXI 2022-11-22 3.4 7.9 27.8 21.3
ZYXI 2022-11-21 3.4 7.8 27.4 21.0
ZYXI 2022-11-18 3.5 8.0 28.1 21.5
ZYXI 2022-11-17 3.5 7.9 28.0 21.4

ZYXI Growth Metrics

    Its 5 year revenue growth rate is now at 286.87%.
  • The 2 year cash and equivalents growth rate now stands at 168.05%.
  • Its 3 year cash and equivalents growth rate is now at 309.25%.
Over the past 55 months, ZYXI's revenue has gone up $122,856,000.

The table below shows ZYXI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 149.728 16.527 18.49
2022-06-30 142.994 12.805 19.724
2022-03-31 137.257 14.008 19.186
2021-12-31 130.301 6.949 17.103
2021-09-30 115.54 -2.285 9.996
2021-06-30 100.78 -6.743 5.222

ZYXI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZYXI has a Quality Grade of A, ranking ahead of 95.17% of graded US stocks.
  • ZYXI's asset turnover comes in at 1.459 -- ranking 6th of 186 Medical Equipment stocks.
  • BLFS, MASI, and DXCM are the stocks whose asset turnover ratios are most correlated with ZYXI.

The table below shows ZYXI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.459 0.778 0.274
2021-06-30 1.385 0.771 0.173
2021-03-31 1.459 0.776 0.254
2020-12-31 1.547 0.783 0.459
2020-09-30 1.683 0.788 0.648
2020-06-30 1.967 0.793 0.802

ZYXI Price Target

For more insight on analysts targets of ZYXI, see our ZYXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.70 Average Broker Recommendation 1.5 (Moderate Buy)

ZYXI Stock Price Chart Interactive Chart >

Price chart for ZYXI

ZYXI Price/Volume Stats

Current price $13.51 52-week high $14.55
Prev. close $13.53 52-week low $4.97
Day low $13.39 Volume 122,600
Day high $13.76 Avg. volume 328,013
50-day MA $10.72 Dividend yield N/A
200-day MA $8.26 Market Cap 505.99M

Zynex Inc. (ZYXI) Company Bio

Zynex Inc., through its subsidiary, markets electro therapy products which help improve life of patients who have functional disabilities. The Company's products include muscle stimulation, inferential, and TENS devices. Zynex products are intended for home use for stroke rehabilitation, spinal cord injury rehabilitation, incontinence, and other applications.

ZYXI Latest News Stream

Event/Time News Detail
Loading, please wait...

ZYXI Latest Social Stream

Loading social stream, please wait...

View Full ZYXI Social Stream

Latest ZYXI News From Around the Web

Below are the latest news stories about ZYNEX INC that investors may wish to consider to help them evaluate ZYXI as an investment opportunity.

Despite recent sales, Zynex, Inc. (NASDAQ:ZYXI) insiders still hold the largest share with a 44% interest

To get a sense of who is truly in control of Zynex, Inc. ( NASDAQ:ZYXI ), it is important to understand the ownership...

Yahoo | November 22, 2022

Zynex Medical to Participate in Piper Sandler 34th Annual Healthcare Conference

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company's management will participate in the Piper Sandler 34th Annual Healthcare Conference. Interested parties can access the webcast on the Events section of the website at https://zynexmed.investorroom.com/ir-home on Wednesday, November 30th, 2022, at 4:30 pm ET.

Yahoo | November 21, 2022

Zynex Named as a Winner in the Deloitte 2022 Technology Fast 500TM Awards for the 4th Consecutive Year

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been ranked 416th in revenue growth among all companies in the U.S. and Canada for revenue growth between 2018 and 2021 on Deloitte's Technology Fast 500. Zynex's revenues grew 308% over that period, with 2021 revenue reaching $130.3 million. The company estimates 2022 reve

Yahoo | November 17, 2022

Zynex, Inc. (NASDAQ:ZYXI) Shares Could Be 47% Below Their Intrinsic Value Estimate

How far off is Zynex, Inc. ( NASDAQ:ZYXI ) from its intrinsic value? Using the most recent financial data, we'll take a...

Yahoo | November 4, 2022

Zynex Announces Additional Share Buyback Program

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common stock. The program will commence on November 1, 2022 and is scheduled to terminate on October 31, 2023 or when the $10.0 million buyback limit is reached.

Yahoo | November 1, 2022

Read More 'ZYXI' Stories Here

ZYXI Price Returns

1-mo 28.42%
3-mo 54.05%
6-mo 93.83%
1-year 15.56%
3-year 41.53%
5-year 432.64%
YTD 49.06%
2021 -25.93%
2020 71.03%
2019 167.69%
2018 -7.55%
2017 960.10%

Continue Researching ZYXI

Here are a few links from around the web to help you further your research on Zynex Inc's stock as an investment opportunity:

Zynex Inc (ZYXI) Stock Price | Nasdaq
Zynex Inc (ZYXI) Stock Quote, History and News - Yahoo Finance
Zynex Inc (ZYXI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.2433 seconds.